Literature DB >> 31772987

Evaluation of Dosimetric Robustness of Carbon Ion Boost Therapy for Anal Carcinoma.

Kim Melanie Kraus1,2, Asja Pfaffenberger2, Oliver Jäkel2,3, Jürgen Debus1,2,3, Florian Sterzing1,2.   

Abstract

PURPOSE: The radiation therapy treatment outcome of human papillomavirus-negative anal carcinoma may be improved by the biological effectiveness of carbon ions. However, abdominal tissue motion can compromise the precision of carbon ion therapy. This work aims to evaluate the dosimetric feasibility of carbon ion boost (CIB) therapy for anal carcinoma.
MATERIALS AND METHODS: An algorithm to generate computed tomographies based on daily magnetic resonance imaging data and deformable image registration was developed. By means of this algorithm, fractional computed tomography data for 54 treatment fractions for 3 different patients with anal carcinoma were derived. The dose for a sequential CIB (CIBseq) treatment plan was recalculated on the fractional computed tomography data and accumulated over the number of fractions. The resulting dose distributions were compared to standard intensity-modulated radiation therapy treatment with an integrated photon boost.
RESULTS: For the investigated patient cases, similar dosimetric results for CIBseq treatment and for intensity-modulated radiation therapy with an integrated photon boost were found. For CIBseq treatment, bladder-filling variation had the strongest influence on the dose distribution. However, the detrimental effects on the mean target dose remained below 1 Gy (RBE) as compared to photon therapy.
CONCLUSION: This study shows the dosimetric feasibility of CIB therapy for anal carcinoma for the first time and gives reason for clinical exploitation of the enhanced biological effect of carbon ions for patients with human papillomavirus-negative anal cancer. © Copyright 2017 International Journal of Particle Therapy 2016.

Entities:  

Keywords:  anal carcinoma; carbon ion therapy; magnetic resonance image–based treatment planning; magnetic resonance–guided radiation therapy

Year:  2017        PMID: 31772987      PMCID: PMC6871606          DOI: 10.14338/IJPT-16-00028.1

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN: 2331-5180


  32 in total

1.  T1/T2*-weighted MRI provides clinically relevant pseudo-CT density data for the pelvic bones in MRI-only based radiotherapy treatment planning.

Authors:  Mika Kapanen; Mikko Tenhunen
Journal:  Acta Oncol       Date:  2012-06-19       Impact factor: 4.089

2.  Feasibility of using MRI alone for 3D radiation treatment planning in brain tumors.

Authors:  R Prabhakar; P K Julka; T Ganesh; A Munshi; R C Joshi; G K Rath
Journal:  Jpn J Clin Oncol       Date:  2007-07-16       Impact factor: 3.019

3.  Dedicated magnetic resonance imaging in the radiotherapy clinic.

Authors:  Mikael Karlsson; Magnus G Karlsson; Tufve Nyholm; Christopher Amies; Björn Zackrisson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-01       Impact factor: 7.038

4.  Respiratory motion management in particle therapy.

Authors:  Eike Rietzel; Christoph Bert
Journal:  Med Phys       Date:  2010-02       Impact factor: 4.071

5.  Generating patient specific pseudo-CT of the head from MR using atlas-based regression.

Authors:  J Sjölund; D Forsberg; M Andersson; H Knutsson
Journal:  Phys Med Biol       Date:  2015-01-07       Impact factor: 3.609

6.  MRI-based treatment planning with pseudo CT generated through atlas registration.

Authors:  Jinsoo Uh; Thomas E Merchant; Yimei Li; Xingyu Li; Chiaho Hua
Journal:  Med Phys       Date:  2014-05       Impact factor: 4.071

7.  Reirradiation Using Carbon Ions in Patients with Locally Recurrent Rectal Cancer at HIT: First Results.

Authors:  Daniel Habermehl; Martin Wagner; Malte Ellerbrock; Markus W Büchler; Oliver Jäkel; Jürgen Debus; Stephanie E Combs
Journal:  Ann Surg Oncol       Date:  2014-11-11       Impact factor: 5.344

8.  MRI-guided prostate radiation therapy planning: Investigation of dosimetric accuracy of MRI-based dose planning.

Authors:  Jonathan Lambert; Peter B Greer; Fred Menk; Jackie Patterson; Joel Parker; Kara Dahl; Sanjiv Gupta; Anne Capp; Chris Wratten; Colin Tang; Mahesh Kumar; Jason Dowling; Sarah Hauville; Cynthia Hughes; Kristen Fisher; Peter Lau; James W Denham; Olivier Salvado
Journal:  Radiother Oncol       Date:  2011-02-19       Impact factor: 6.280

9.  Utilising pseudo-CT data for dose calculation and plan optimization in adaptive radiotherapy.

Authors:  Brendan Whelan; Shivani Kumar; Jason Dowling; Jarrad Begg; Jonathan Lambert; Karen Lim; Shalini K Vinod; Peter B Greer; Lois Holloway
Journal:  Australas Phys Eng Sci Med       Date:  2015-09-04       Impact factor: 1.430

10.  Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial.

Authors:  Stephanie E Combs; Meinhard Kieser; Daniel Habermehl; Jürgen Weitz; Dirk Jäger; Piero Fossati; Roberto Orrechia; Rita Engenhart-Cabillic; Richard Pötter; Manjit Dosanjh; Oliver Jäkel; Markus W Büchler; Jürgen Debus
Journal:  BMC Cancer       Date:  2012-04-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.